Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200 at the European Congress of Rheumatology (EULAR) 2026, held June 3-6 in London, UK. LFD-200 is a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells. The Phase 1 study in healthy participants demonstrated that LFD-200 was well tolerated and exhibited dose-responsive anti-inflammatory activity without impacting serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity.
The findings are significant because systemic glucocorticoids, while effective for inflammatory conditions, are associated with serious side effects such as adrenal suppression, osteoporosis, and metabolic disturbances. By targeting glucocorticoids directly to immune cells, LFD-200 aims to achieve local anti-inflammatory effects while minimizing systemic exposure. According to the company, the absence of cortisol suppression in healthy participants suggests that LFD-200 may avoid the typical glucocorticoid toxicity profile.
Dosing in the Phase 1 study for patients with moderate to severe rheumatoid arthritis is ongoing, with data expected by the end of 2026. This next phase will evaluate the drug's efficacy and safety in the target patient population. The company plans to present the healthy participant data in a poster at EULAR, with further details available on their website.
Lifordi is leveraging the success of ADCs in oncology to address autoimmune diseases, a novel approach that has garnered attention from investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures. The company is also applying its drug delivery platform to other payloads, such as antisense oligonucleotides, siRNA, and small molecules, broadening its potential impact across immune-mediated conditions.
The announcement at EULAR 2026 underscores the growing interest in targeted therapies for autoimmune diseases that can reduce the burden of chronic steroid use. With rheumatoid arthritis affecting millions worldwide, a safer and effective treatment option could significantly improve patient outcomes. Lifordi's progress with LFD-200 represents a step forward in the development of next-generation therapies for inflammatory disorders.
